Recruiting PHASE2 Chronic Lymphocytic Leukemia

New treatment option for Chronic Lymphocytic Leukemia

Official title Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

ClinicalTrials.gov ID: NCT06043674

What this study is testing

What is Glofitamab?

Glofitamab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for chronic lymphocytic leukemia.

Also referred to as RO7082859.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing: This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: Glofitamab (a T-cell bispecific humanized monoclonal antibody) Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) Polatuzumab vedotin (an antibody-drug conjugate) Pirtobrutinib (a selective inhibitor of BTK) Atezolizumab (a humanized immunoglobulin monoclonal antibody) Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)

Phase 2: a mid-size study of how well it works
Time commitment: about 10 years

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older

You may be able to join if

Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven...
Cohort-specific eligibility criteria:
Glofitamab monotherapy cohort: Patients with either relapsed/refractory or previously untreated Richter's Transformation.
Glofitamab + polatuzumab vedotin cohort: Patients with previously untreated RT. After the first 10 patients are enrolled in this cohort irrespective...
Glofitamab + pirtobrutinib cohort: Patients with previously untreated RT and prior BTK inhibitor exposure (with enrollment to begin only after the...

You likely can't join if

Patients with the Hodgkin variant transformation of CLL will be excluded.
No prior anti-CD20 bispecific antibody is allowed. No prior, polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing...
Subject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of treatment...
Prior treatment with CAR T-cell therapy within 30 days before first study treatment administration.
Subject has not recovered to less than Grade 1 clinically significant adverse effect(s)/toxicity from prior anti-cancer therapy including...
Patients with bulky cervical adenopathy that is compressing the upper airway and could result in significant further airway compression during a...

See the full eligibility criteria

Who can join

Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transformation to diffuse large B-cell lymphoma (DLBCL), consistent with...
Cohort-specific eligibility criteria:
Glofitamab monotherapy cohort: Patients with either relapsed/refractory or previously untreated Richter's Transformation.
Glofitamab + polatuzumab vedotin cohort: Patients with previously untreated RT. After the first 10 patients are enrolled in this cohort irrespective of prior BTKi exposure status, the remainder of the patients enrolled...
Glofitamab + pirtobrutinib cohort: Patients with previously untreated RT and prior BTK inhibitor exposure (with enrollment to begin only after the first 10 patients are accrued to the polatuzumab combination cohort)...
Glofitamab + atezolizumab cohort: Patients with relapsed/refractory RT. Patients are required to have received ≥ 1 prior line of therapy. Patients cannot have prior atezolizumab exposure.
Age ≥18 years.
ECOG performance status of 0-2 (Appendix A).
For patients receiving glofitamab monotherapy, glofitamab in combination with polatuzumab vedotin, or glofitamab in combination with atezolizumab, participants must meet the following organ and marrow function as...
Absolute neutrophil count must be \> 1.0 x10\^9/L (growth factor allowed to achieve), unless patients have significant bone marrow involvement of their malignancy confirmed on biopsy.
Platelets must be \> 30 x10\^9/L, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
Creatinine \ 50 ml/min
Total bilirubin \< 1.5 X ULN
people with Gilbert's Syndrome or resolving autoimmune hemolytic anemia may have a bilirubin up to 3.0 X ULN
AST/ALT \< 3.0 X ULN, unless documented liver involvement by lymphoma
For patients receiving glofitamab in combination with pirtobrutinib, participants must meet the following:
Absolute neutrophil count must be \> 1.0 x109/L (growth factor \>7 days prior allowed to achieve), unless patients have significant bone marrow involvement of their malignancy confirmed on biopsy.
Hemoglobin \> 8 g/dL, independent of transfusion within 7 days of screening, unless patients have bone marrow involvement of their malignancy confirmed on biopsy
Platelets must be \> 50 x109/L, independent of transfusion within 7 days of screening
Estimated CrCl \> 50 ml/min according to Cockcroft/Gault formula
AST/ALT \< 3.0 X ULN, or \< 5.0 X ULN with documented liver involvement by lymphoma
Total bilirubin \< 1.5 X ULN or \< 3.0 x ULN with documented liver involvement by lymphoma and/or Gilbert's Disease
Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.
The patient is able to take oral medications
Patients who have undergone prior allogeneic transplantation are potentially eligible if their transplant day 0 is \> 6 months from their first dose of treatment and as follows:
For patients receiving glofitamab monotherapy or glofitamab in combination with polatuzumab vedotin, all of the following must additionally be true:
No current or prior Grade 3/4 graft versus host disease (GVHD)
Stable off of immunosuppression for at least 2 months prior to receiving their first dose of treatment on study
For patients receiving glofitamab in combination with pirtobrutinib, all of the following must additionally be true:
No active/current GVHD
No prior history of Grade 3/4 GVHD
Stable off of immunosuppression for at least 2 months prior to receiving their first dose of treatment on study
For patients receiving atezolizumab, no prior allogeneic hematopoietic cell transplantation is allowed.
Willingness to remain abstinent (refrain from heterosexual intercourse) or to use effective contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least the following...
Female patients: at least 18 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 5 months after the last dose of atezolizumab, or 9 months after the last dose of polatuzumab...
Male patients: at least 3 months after pre-treatment with obinutuzumab, or 2 months after the last dose of glofitamab, or 5 months after the last dose of polatuzumab vedotin, or 2 months after the last dose of...
Examples of highly effective contraceptive methods with a failure rate of \<1% per year include: Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit...
For female patients, willingness to refrain from donating ova during the same periods described in section 3.1.6 for female patients. For male patients, willingness to refrain from donating sperm during the same periods...
Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)

What rules you out

Patients with the Hodgkin variant transformation of CLL will be excluded.
No prior anti-CD20 bispecific antibody is allowed. No prior, polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing combination arm. No prior, or atezolizumab therapy is allowed for patients...
Subject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of treatment: investigational agents, targeted therapies, e.g. tyrosine kinase inhibitors...
Prior treatment with CAR T-cell therapy within 30 days before first study treatment administration.
Subject has not recovered to less than Grade 1 clinically significant adverse effect(s)/toxicity from prior anti-cancer therapy including immunotherapy, with the exception of alopecia, endocrinopathy managed with...
Patients with bulky cervical adenopathy that is compressing the upper airway and could result in significant further airway compression during a tumor flare event.
History of other malignancies, except:
CLL/SLL
Malignancy treated with curative intent and with no known active disease present before the first dose of study drug and felt to be at low risk for recurrence by treating physician
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Adequately treated carcinoma in situ without evidence of disease
Low-risk prostate cancer on active surveillance
For patients receiving polatuzumab vedotin: Current \> Grade 1 peripheral neuropathy.
Any history of immune-related ≥ Grade 3 AE with the exception of endocrinopathy managed with replacement therapy.
Patient with history of confirmed progressive multifocal leukoencephalopathy (PML).
Current or past history of central nervous system (CNS) disease involvement or history of leptomeningeal disease.
Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease (Note: patients with a history of stroke who have not experienced a stroke or transient ischemic attack in...
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
Prior solid organ transplantation.
History of known or suspected hemophagocytic lymphohistiocytosis (HLH).
Active or history of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel...
Patients with a remote history of, or well controlled, autoimmune disease may be eligible to enroll after consultation with the study PI.
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone and patients with controlled Type 1 diabetes mellitus who are on an insulin regimen can be included.
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided that the disease is...
For patients enrolling to the pirtobrutinib combination arm, patients with the following should be discussed with the Sponsor-Investigator prior to enrollment: active uncontrolled auto-immune cytopenia (e.g., autoimmune...
Patients who require systemic immunosuppressive therapy for an ongoing medical condition will be excluded with the exception of corticosteroid use for disease-related symptom control. Treatment for autoimmune disease...
Note the following are permitted: use of inhaled corticosteroids, use of mineralocorticoids for management of orthostatic hypotension.
Corticosteroids for lymphoma symptom control is allowed provided patients are on a stable dose as per discretion of the treating investigator and in discussion with the Sponsor-Investigator.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization.
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general...
History of Human Immunodeficiency Virus (HIV):
For patients receiving glofitamab in combination with pirtobrutinib, patients who have tested positive for HIV are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. For patients with...
For patients in all other cohorts, only those without controlled disease (controlled disease defined as CD4 count greater than or equal to 200 per microliter, undetectable viral load, and stable anti-retroviral therapy)...
History of Human T-Cell Leukemia Virus 1 (HTLV-1) infection.
Known active cytomegalovirus (CMV) infection.
Clinically significant liver disease, including cirrhosis and active viral or non-viral hepatitis. Patients who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative viral load...
Patients with a known active infection or any major episode of infection requiring hospitalization or treatment with IV antimicrobial within 4 weeks prior to first study drug. Patients receiving prophylactic antibiotics...
Patients should not have received immunization with live vaccines within 28 days prior to start of study treatment. In addition, patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study...
Patients with any one of the following currently or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, unstable angina, or coronary/peripheral artery...
Patients with New York Heart Association Class III or IV heart failure or with Objective Assessment Class C or D cardiac disease.
For patients receiving pirtobrutinib:
Significant cardiovascular disease defined as:
unstable angina or acute coronary syndrome within the past 2 months prior to randomization
history of myocardial infarction within 3 months prior to randomization or
documented LVEF by any method of ≤ 40% in the 12 months prior to randomization
Uncontrolled or symptomatic arrhythmias
Note: patients with atrial fibrillation are allowed as long as they are adequately rate-controlled.)
Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
Prolongation of the QT interval corrected for heart rate (QTcF) \> 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33).
Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug...
Correction for underlying bundle branch block (BBB) allowed.
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.
Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks...
Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.
Have a known hypersensitivity to any of the excipients of Pirtobrutinib or to any intended study medications.
Patients who experienced a major bleeding event or grade ≥ 3 arrhythmia on prior treatment with a BTK inhibitor. Note: Major bleeding is defined as bleeding having one or more of the following features: potentially...
History of bleeding disorders (e.g. von Willebrand's disease, hemophilia).
History of stroke or intracranial hemorrhage within 6 months of starting study therapy.
Inability to comply with protocol mandated hospitalizations and restrictions.
Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.
Any other diseases, metabolic dysfunction, physical examination finding, mental status or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an...

The study team makes the final eligibility decision.

Where it's taking place

Atlanta, Georgia, United States
Boston, Massachusetts, United States
Chapel Hill, North Carolina, United States
Columbus, Ohio, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The study runs about 10 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Atlanta, Georgia, United States; Boston, Massachusetts, United States; Chapel Hill, North Carolina, United States; Columbus, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.